Raymond James Financial Services Advisors Inc. bought a new position in Voyager Therapeutics Inc (NASDAQ:VYGR) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 54,488 shares of the company’s stock, valued at approximately $1,122,000. Raymond James Financial Services Advisors Inc. owned about 0.20% of Voyager Therapeutics at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. grew its position in shares of Voyager Therapeutics by 3.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 28,921 shares of the company’s stock valued at $383,000 after purchasing an additional 1,026 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of Voyager Therapeutics by 57.7% in the second quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock valued at $106,000 after purchasing an additional 4,343 shares in the last quarter. Bessemer Group Inc. grew its position in shares of Voyager Therapeutics by 148.1% in the second quarter. Bessemer Group Inc. now owns 44,828 shares of the company’s stock valued at $402,000 after purchasing an additional 26,763 shares in the last quarter. Rhumbline Advisers grew its position in shares of Voyager Therapeutics by 34.7% in the second quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock valued at $144,000 after purchasing an additional 4,144 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Voyager Therapeutics by 20.9% in the second quarter. Bank of New York Mellon Corp now owns 53,225 shares of the company’s stock valued at $477,000 after purchasing an additional 9,207 shares in the last quarter. 35.97% of the stock is owned by institutional investors and hedge funds.

VYGR has been the subject of several recent research reports. Wedbush reiterated a “positive” rating and issued a $31.00 price target (down from $36.00) on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Canaccord Genuity began coverage on Voyager Therapeutics in a research report on Friday, October 27th. They issued a “buy” rating and a $35.00 price target for the company. Zacks Investment Research lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Cowen reissued a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Finally, ValuEngine lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $26.33.

In related news, insider Bernard Ravina sold 16,470 shares of Voyager Therapeutics stock in a transaction on Monday, September 11th. The stock was sold at an average price of $12.87, for a total transaction of $211,968.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 38,430 shares of company stock valued at $562,890 in the last three months. 8.00% of the stock is owned by corporate insiders.

Shares of Voyager Therapeutics Inc (NASDAQ:VYGR) opened at $14.44 on Friday. Voyager Therapeutics Inc has a 52 week low of $8.10 and a 52 week high of $25.99.

COPYRIGHT VIOLATION NOTICE: “54,488 Shares in Voyager Therapeutics Inc (VYGR) Purchased by Raymond James Financial Services Advisors Inc.” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.dailypolitical.com/2017/12/02/54488-shares-in-voyager-therapeutics-inc-vygr-purchased-by-raymond-james-financial-services-advisors-inc.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics Inc (NASDAQ:VYGR).

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.